(0.00%) 5 187.67 points
(0.44%) 39 056 points
(-0.18%) 16 303 points
(0.39%) $79.30
(-0.37%) $2.18
(-0.26%) $2 316.20
(-0.04%) $27.59
(0.28%) $987.40
(0.03%) $0.930
(0.06%) $10.90
(0.02%) $0.800
(0.02%) $91.76
2.34% $ 23.62
@ $21.78
Wydano: 14 vas. 2024 @ 20:47
Zwrot: 8.47%
Poprzedni sygnał: vas. 14 - 16:30
Poprzedni sygnał:
Zwrot: -1.94 %
Live Chart Being Loaded With Signals
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics...
Stats | |
---|---|
Dzisiejszy wolumen | 227 971 |
Średni wolumen | 406 906 |
Kapitalizacja rynkowa | 1.01B |
EPS | $0 ( 2024-05-02 ) |
Następna data zysków | ( $-1.240 ) 2024-05-16 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.37 |
ATR14 | $0.0450 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Baker Bros. Advisors Lp | Buy | 12 000 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 12 000 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 24 000 | Share Option (Right to Buy) |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 0 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 0 | American Depositary Shares |
INSIDER POWER |
---|
72.47 |
Last 94 transactions |
Buy: 1 498 500 | Sell: 230 741 |
Wolumen Korelacja
Bicycle Therapeutics PLC Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
GSMG | 0.966 |
SIRI | 0.954 |
SINT | 0.953 |
JAGX | 0.951 |
VWE | 0.951 |
DBGI | 0.948 |
NAKD | 0.948 |
RPTX | 0.944 |
EQ | 0.941 |
YJ | 0.941 |
10 Najbardziej negatywne korelacje | |
---|---|
INTA | -0.972 |
AGGR | -0.963 |
BIOS | -0.96 |
FICV | -0.959 |
ALSA | -0.957 |
TBSA | -0.957 |
NCAC | -0.956 |
MLTX | -0.955 |
PPYAU | -0.955 |
LVRA | -0.954 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Bicycle Therapeutics PLC Korelacja - Waluta/Towar
Bicycle Therapeutics PLC Finanse
Annual | 2023 |
Przychody: | $26.98M |
Zysk brutto: | $20.40M (75.64 %) |
EPS: | $-5.08 |
FY | 2023 |
Przychody: | $26.98M |
Zysk brutto: | $20.40M (75.64 %) |
EPS: | $-5.08 |
FY | 2022 |
Przychody: | $14.46M |
Zysk brutto: | $10.78M (74.51 %) |
EPS: | $-3.80 |
FY | 2021 |
Przychody: | $11.70M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.67 |
Financial Reports:
No articles found.
Bicycle Therapeutics PLC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej